Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs

Subrata Ghosh (), Lianne S. Gensler (), Zijiang Yang (), Chris Gasink (), Soumya D. Chakravarty (), Kamyar Farahi (), Paraneedharan Ramachandran (), Elyssa Ott () and Bruce E. Strober ()
Additional contact information
Subrata Ghosh: University of Birmingham
Lianne S. Gensler: University of California San Francisco
Zijiang Yang: Janssen Research & Development, LLC
Chris Gasink: Janssen Scientific Affairs, LLC
Soumya D. Chakravarty: Janssen Scientific Affairs, LLC
Kamyar Farahi: Janssen Scientific Affairs, LLC
Paraneedharan Ramachandran: Janssen Research & Development, LLC
Elyssa Ott: Janssen Scientific Affairs, LLC
Bruce E. Strober: University of Connecticut Health Center

Drug Safety, 2019, vol. 42, issue 6, No 14, 809-809

Abstract: In the original publication of this article, the following correction should be noted in Table 5.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-019-00816-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:42:y:2019:i:6:d:10.1007_s40264-019-00816-3

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-019-00816-3

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().